Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

Drugs ◽  
2020 ◽  
Vol 80 (17) ◽  
pp. 1811-1830
Author(s):  
Megan E. Tesch ◽  
Karen A. Gelmon
Keyword(s):  
Breast Cancer ◽  
Treatment Sequencing

scholarly journals DISTINCT TEMPORALITIES IN THE BREAST CANCER DISEASE PROCESS

2014 ◽  
Vol 48 (spe2) ◽  
pp. 73-80 ◽  
Author(s):  
Janderléia Valéria Dolina ◽  
Roseney Bellato ◽  
Laura Filomena Santos de Araújo
Keyword(s):  
Breast Cancer ◽  
Medical Therapy ◽  
Life Story ◽  
Disease Process ◽  
Cancer Disease ◽  
Personal Time ◽  
Data Collection Process ◽  
Treatment Sequencing ◽  
Therapy Protocol ◽  
Sequencing Process

Comprehensive approach study aimed understanding the reflections and contrasts between personal time and medical therapy protocol time in the life of a young woman with breast cancer. Addressed as a situational study and grounded in Beth’s life story about getting sick and dying of cancer at age 34, the study’s data collection process employed interviews, observation and medical record analysis. The construction of the analytic-synthetic box based on the chronology of Beth’s clinical progression, treatment phases and temporal perception of occurrences enabled us to point out a linear medical therapy protocol time identified by the diagnosis and treatment sequencing process. On the other hand, Beth’s experienced time was marked by simultaneous and non-linear events that generated suffering resulting from the disease. Such comprehension highlights the need for healthcare professionals to take into account the time experienced by the patient, thus providing an indispensable cancer therapeutic protocol with a personal character.

Visualizing treatment patterns and survival in metastatic breast cancer.

2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 316-316
Author(s):  
Aidan Gilbert ◽  
Courtney Williams ◽  
Pravinkumar Kandhare ◽  
Arie Nakhmani ◽  
Stephen C. Meersman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Targeted Therapy ◽  
Quantitative Methods ◽  
Metastatic Breast ◽  
Treatment Patterns ◽  
Her2 Status ◽  
Duration Of Treatment ◽  
Treatment Sequencing ◽  
The Relationship

316 Background: Optimal treatment sequencing (i.e., the order in which drugs are given) for metastatic breast cancer (MBC) is unknown. We aimed to develop an approach to visualize treatment patterns and survival in MBC. Methods: This retrospective study utilized ASCO’s CancerLinQ Discovery® database generated from electronic health records. Subjects included 3,312 women aged ≥18 years who were diagnosed with and received treatment for MBC after 1980. Hormone receptor (HR) status was determined by concordant diagnosis and treatment records. Human epidermal growth factor (HER2) status was determined by delivery of HER2-targeted therapy. Ordered and administered treatments were included. We created spatiotemporal plots of treatment patterns for HR+/HER2-, HER2+, and triple negative (TN) MBC. Individuals were represented on the Y-axis, and time on the X-axis with development of MBC aligned at time 0. Treatment classes were identified by colors: hormone therapies in shades of red, chemotherapies in shades of blue, HER2-targeted therapies in shades of green, and novel therapies in shades of orange. Concurrent treatments were represented by split bars. An overlaid Kaplan-Meier curve allowed for observations about the relationship between survival and treatment. Results: We developed a novel visualization approach to simultaneously display heterogeneous, longitudinal treatments and survival. Median survival after first documentation of MBC was 3.1 (IQR 1.4-7.2), 1.3 (IQR 0.6-2.8), and 2.6 (IQR 1.0-5.2) years for HR+/HER2-, TN, and HER2+ MBC, respectively. Patients with longer survival often had long duration of initial therapy, suggesting a more indolent or responsive disease. Substantial heterogeneity in treatment sequencing was observed for HR+HER2- and TN cohorts. In the HER2+ cohort, HER2-targeted therapy was commonly administered for the duration of treatment with more homogeneous sequencing. Conclusions: This novel visualization approach allows for observing the relationship between treatment patterns and survival, which is challenging to demonstrate with traditional quantitative methods. This approach can generate hypotheses regarding impact of treatment patterns on survival.

Visualization of Sequential Treatments in Metastatic Breast Cancer

2020 ◽  
pp. 1-8
Author(s):  
Gabrielle B. Rocque ◽  
Pravinkumar G. Kandhare ◽  
Courtney P. Williams ◽  
Arie Nakhmani ◽  
Andres Azuero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Median Survival ◽  
Hormonal Therapy ◽  
De Novo ◽  
Metastatic Breast ◽  
Treatment Sequence ◽  
Differential Survival ◽  
Treatment Sequencing ◽  
The Impact

PURPOSE Treatment sequencing of metastatic breast cancer (MBC) is heterogeneous. The primary objective of this study was to develop a visualization technique to understand population-level treatment sequencing for MBC. Secondary outcomes were to describe the heterogeneity of MBC treatment sequencing, as measured by the proportion of patients with a rare sequence, and to generate hypotheses about the impact of sequencing on overall survival. METHODS This retrospective review evaluated treatment sequencing for patients with MBC in the SEER–Medicare database. Patients with either de novo MBC or International Classification of Diseases, Ninth Revision, diagnosis codes for secondary metastasis (197.XX-198.XX) on two separate dates, excluding breast (198.81, 198.82, 198.2) and lymph nodes (196.XX), were included. Complete Medicare Parts A, B, and D coverage was required. A treatment sequence that fewer than 11 patients received was considered rare. A graphic was created with each nonrare treatment-sequence grouping on the y-axis and time on the x-axis. Bars representing time on hormonal therapy, chemotherapy, human epidermal growth factor receptor 2–targeted therapy, and other targeted therapies were color coded. Kaplan-Meier–like curves were overlaid on treatment maps, using estimated median survival for each sequence. RESULTS Of 6,639 patients with MBC, 56% received a treatment sequence that fewer than 11 other patients received, with 2,985 other unique, rare sequences were identified. Sequence visualization demonstrated differential survival, with longer median survival for those initially receiving hormonal therapy. The median time receiving initial treatment was similar for patients receiving first-line chemotherapy. CONCLUSION Treatment-sequence visualization can enhance the capacity to effectively conceptualize treatment patterns and patient outcomes.

Treatment sequencing and duration among HR+/HER2- advanced breast cancer patients in community-based oncology practices.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e11549-e11549
Author(s):  
Yanni Hao ◽  
James E. Signorovitch ◽  
Alexander R. Macalalad ◽  
Eric Qiong Wu ◽  
Peggy L. Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Community Based ◽  
Treatment Sequencing

scholarly journals Real-world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets

2019 ◽  
Vol 30 ◽  
pp. v137 ◽  
Author(s):  
A.W.B. Horne ◽  
M. McMenemy ◽  
E. Holly ◽  
N. Rigglesford ◽  
P. Linksted ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Treatment Sequencing ◽  
Secondary Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document